BTK and mantle cell lymphoma: The Bruton tyrosine kinase (BTK) inhibitors are FDA-approved as single agents in r/r MCL in the second (covalent inhibitors) or third line (non-covalent inhibitors) and are a backbone for combination with investigational targeted therapies for relapsed/refractory (r/r) MCL.